Title:
β2GPI GENE-SILENCING RNAi MEDICINE COMPOSITION
Document Type and Number:
WIPO Patent Application WO2017010573
Kind Code:
A1
Abstract:
The invention provides lipid particles, etc., containing a double-stranded nucleic acid as a drug, and a cationic lipid represented by formula (A), etc., the double-stranded nucleic acid comprising a sense strand and an antisense strand including a double-stranded region of at least 11 base pairs and is complementary to a target β2GPI mRNA sequence selected from the group listed in Table 2-1 to Table 2-16 in an oligonucleotide strand of a strand length of 17-30 nucleotides in the antisense strand.
Inventors:
NAGATOMO KAZUTAKA (JP)
MASUDA KAZUHIRO (JP)
KANDA MINAKO (JP)
YAMADA YOJI (JP)
IWAI HIROTO (JP)
NAOI TOMOYUKI (JP)
MASUDA KAZUHIRO (JP)
KANDA MINAKO (JP)
YAMADA YOJI (JP)
IWAI HIROTO (JP)
NAOI TOMOYUKI (JP)
Application Number:
PCT/JP2016/071076
Publication Date:
January 19, 2017
Filing Date:
July 15, 2016
Export Citation:
Assignee:
KYOWA HAKKO KIRIN CO LTD (JP)
International Classes:
A61K48/00; A61K9/127; A61K31/7088; A61K47/18; A61K47/22; A61P7/02; A61P37/06
Domestic Patent References:
| WO2010054401A1 | 2010-05-14 |
Other References:
GUERIN JAN ET AL.: "Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 4, 25 January 2002 (2002-01-25), pages 2644 - 9, XP055345368
Attorney, Agent or Firm:
INABA, Yoshiyuki et al. (JP)
Download PDF: